mens, possibly including biologically targeted drugs, could be considered in those with FDG-nonavid tumors.
by surgery compared with surgery alone have been presented [10, 11] . The Medical Research Council Adjuvant Gastric Infusional Chemotherapy (MAGIC) trial randomly assigned patients with resectable adenocarcinoma of the stomach or lower esophagus either to perioperative chemotherapy (250 patients) or to surgery alone (253 patients). Chemotherapy consisted of three preoperative and three postoperative cycles of intravenous epirubicin, cisplatin, and continuous infusional 5-fl uorouracil (FU). Chemotherapy-related adverse effects were moderate. Postoperative complications and 30-day mortality did not differ in patients with and without perioperative chemotherapy (46% versus 45% and 5.6% versus 5.9%, respectively). The resected tumors were signifi cantly smaller and less advanced in T-and N-stage in the group who underwent preoperative chemotherapy. With a median follow-up of 4 years, 149 patients in the group with perioperative chemotherapy have died, compared with 170 patients in the surgery-only group. Compared with patients receiving surgery alone, the patients with perioperative chemotherapy had signifi cantly improved overall (P = 0.009) and progression-free survivals (P < 0.001). The 5-year survival rate was 36% for patients with perioperative chemotherapy and 23% for patients with surgery alone [10] . In 2007, at the American Society of Clinical Oncology (ASCO) conference, the French presented their Fédération Nationale des Centres de Lutte Contre le Cancer (FNCLCC) Actions Concertées dans les Cancer Colorectaux et Digestifs-07 (ACCORD-07) Fédération Francophone de la Cancérologie Digestif (FFCD) 9703 trial, which confi rmed these results. In this trial, a combination of infusional 5-FU and cisplatin, given for two to three cycles preoperatively, was delivered in patients with resectable gastric or esophageal adenocarcinoma [11] . Postoperative chemotherapy was recommended in patients with response to preoperative chemotherapy or in those with stable disease with positive lymph nodes. A total of 224 patients (111 patients with surgery alone and 113 patients with perioperative chemotherapy) were included. The rate of resections with tumor-free margins (R0) was signifi cantly higher after preoperative chemotherapy (84% versus 73%; P = 0.04). After induction chemotherapy, the disease-free (P = 0.003) and overall survivals (P = 0.02) were superior to those in patients with surgery alone. The reported 5-year survival rates of 38% with chemotherapy and 24% with surgery alone were similar to the rates in the MAGIC trial. In both studies, only a small percentage (MAGIC trial, 42%; ACCORD-07, 50%) of patients completed both pre-and postoperative chemotherapy, whereas in 86% and 87% of the patients preoperative chemotherapy was administered as specifi ed in the study protocol. The results of both studies are summarized in Table 1 . It is not possible to attribute the survival benefi t to preoperative chemotherapy only, because both studies evaluated perioperative chemotherapy. The study design does not allow for a separate analysis of the impact of the postoperative chemotherapy on the improvement in overall survival.
Both studies have been criticized because of the long recruitment period (8 years each), the insuffi cient preoperative staging, the inaccurate histopathological workup, and the high dropout rate in the postoperative treatment arm. Neither a clinical nor a histopathological response evaluation was performed in either study. 
Response evaluation
Since 1999 it has been perceived that patients who respond to induction chemotherapy have a signifi cantly improved survival compared to patients who do not respond to induction treatment [12] . However, no standardized concepts for response evaluation have been established so far. Clinical response evaluation by morphologic imaging techniques has specifi c limitations in gastric cancer. According to the strict WHO criteria, gastric cancer is not bidimensionally measureable [13] .
Criteria from the Response Evaluation Criteria in Solid Tumor (RECIST) Group ratings, which use onedimensional measurements, are, in principle, applicable for gastric cancer [14] . However, the measurement of wall thickness is critically dependent on the distension of the stomach during the examination. RECIST criteria have been used in only a few phase II trials with induction therapy so far [15] [16] [17] [18] [19] . Careful clinical response evaluation, with a combination of endoluminal ultrasound, endoscopy, and computed tomography (CT) scans used for restaging after one cycle or before surgery, is predictive of histopathological regression and prognosis at experienced centers [5, 12, [20] [21] [22] [23] .
Often histopathological regression is used for response evaluation. Yet including only patients who undergo resection would cause a signifi cant bias; therefore, clinical response evaluation has to be included, and patients with progression during chemotherapy have to be classifi ed as nonresponding. Although similar criteria for histopathological regression have been used in several studies, these criteria are not standardized and may be investigator-dependent. A modifi ed regression score of Mandard et al. [24] , who fi rst described histopathological regression for esophageal cancer after chemoradiotherapy, was published by Becker et al. [25] for gastric cancer. Applying this scoring system, patients with less than 10% residual tumor cells after neoadjuvant treatment are classifi ed as histopathological responders (score 1a, complete response and score 1b, less than 10% residual tumor cells). In other publications, only patients with complete tumor regression are classifi ed as histopathological responders [26, 27] . In contrast, Shah et al. [28] defi ned patients with less than 50% residual tumor cells as histopathological responders.
All applied types of response evaluation, either clinical or histopathological, are strongly correlated with prognosis. Homogenization of the scoring systems used for clinical and histopathological response evaluation would be desirable in the future to make studies of induction therapy more easily comparable with each other.
A model for metabolic response evaluation in adenocarcinomas of the esophagogastric junction (AEG)
Measurements of early changes in tumor glucose uptake after only 2 weeks of induction therapy, with the use of 18-fl uorodeoxyglucose-positron emission tomography (FDG-PET), have yielded reproducible results that can be used for the prediction of clinical and histopathological response after the end of neoadjuvant treatment in type I and II adenocarcinomas of the distal esophagus [21, 22] . The cutoff value of a decrease of more than 35% of the initial standard uptake value (SUV) after 2 weeks of induction therapy predicted response and prognosis [21] . Our major interest was to correctly identify nonresponding patients early in the course of therapy, to avoid toxic, expensive, and ineffective treatment. The cutoff value was confi rmed in an independent patient population [22] . Specifi cally, we have noted that, when using the cutoff value of −35% decrease of initial SUV, PET correctly identifi es nonresponding patients after 2 weeks of chemotherapy with a high accuracy [21, 22] . This fi nding was used to tailor treatment to the individual patient in the MUNICON trial (the Metabolic response evalUatioN for Individualisation of neoadjuvant Chemotherapy in oesOphageal and oesophagogastric adeNocarcinoma) [29, 30] . Metabolic responders after 2 weeks of induction chemotherapy continued to receive chemotherapy for a maximum of 12 weeks before undergoing surgery, whereas metabolic nonresponders discontinued chemotherapy and were immediately transferred to surgery after only 2 weeks of chemotherapy. In this trial, 110 patients were evaluable for metabolic response and 49% were classifi ed as metabolic responders; 104 patients had resections. Histopathological regression with less than 10% residual tumor cells was achieved in 58% of the metabolic responders, but no histopathological regression 1a or 1b was achieved in metabolic nonresponders. The median survival for metabolic responders has not yet been reached, whereas the median survival for metabolic nonresponders is 25.8 months (P = 0.015). The eventfree survival was 29.7 months for metabolic responders and 14.1 months in metabolic nonresponders (P = 0.002) [29, 30] . Interestingly, metabolic nonresponders who had resections after only 2 weeks of induction therapy had a slightly better survival compared to that of the historic control metabolic nonresponders who completed two cycles of neoadjuvant treatment (Fig. 1 ) [22, 29] . The MUNICON study confi rmed again, prospectively, the usefulness of metabolic response evaluation in AEG I and II and showed, for the fi rst time, that a PET-guided treatment algorithm was feasible in the multidisciplinary treatment setting and that it led to favorable treatment results. Based on these results, the tailoring of multimodal treatment in accordance with individual tumor biology might be possible in future randomized trials.
FDG-PET in gastric cancer
In gastric cancer, current imaging modalities or molecular markers cannot reliably predict therapy response before or early in the course of treatment -the time when this information is most important in gastric cancer [31, 32] . As noted above, PET imaging after 2 weeks of chemotherapy was signifi cantly correlated with histopathological response and prognosis in patients with AEG I/II [21, 22, 29] . Interestingly, approximately one-third of gastric cancer patients, even those with locally advanced tumors, initially have insuffi cient FDG uptake for quantifi cation (Table 2) [20, 28, [33] [34] [35] [36] [37] [38] [39] [40] [41] . FDG-nonavid tumors are associated with diffuse Lauren classifi cation, small tumor size, good differentiation, mucinous content, and localization in the distal third (Table 3) [33] [34] [35] [36] [37] [38] 41] . We have shown that a decrease in tumor FDG uptake by more than 35% of the baseline value allowed for accurate prediction of response in patients with gastric cancer 14 days after the initiation of cisplatin-based polychemotherapy, with an overall accuracy of 83% for 35 patients if image contrast was suffi cient for quantitative analysis. Metabolic response in FDG-avid gastric cancer, including AEG II, showed an association with metabolic and histopathological or clinical response (Table 4) . For patients with a metabolic response, median survival was not reached (2-year survival rate, 90%); for patients without a metabolic response, median survival was 18.9 months (2-year survival, 25%; P = 0.002; Fig. 2 ) [20] . This study used a cutoff defi ning the metabolic response derived from patients suffering from locally advanced AEG after 2 weeks of induction therapy [21] . A different time point and cutoff value was determined by Shah et al. [28] for 41 patients with gastric cancer staged cT2-4NanycM0. They evaluated, retrospectively, a decrease of more than 45% of the initial SUV after 35 days as the best criterion for predicting response and prognosis. The cutoff was signifi cantly correlated with histopathological response (less than 50% residual tumor; P = 0.007) Fig. 1A,B . Historical comparison of overall survival of A patients with chemotherapy for 3 months and B patients with response-based neoadjuvant treatment. The median survival of metabolic (PET) nonresponders was 26 months in patients with immediate resection after 2 weeks of chemotherapy and 18 months in patients with 3-month chemotherapy in the historical control group. Stopping chemotherapy did not seem to worsen the prognosis of the metabolic nonresponders. PET, Positron emission tomography [22, 29] n, Number question is whether an early metabolic response evaluation is possible in patients with AEG and the stomach treated with preoperative chemoradiotherapy [8, 42] . No data addressing this problem are available so far. As noted above, up to 40% of gastric carcinomas are FDGnonavid and are therefore not suitable for response monitoring using the PET tracer 18F-FDG. Interestingly, the response rate and prognosis of these patients seems to be similar to those in metabolic nonresponders, probably defi ning a subgroup of biologically unfavorable tumors ( Fig. 3 ; our own unpublished data). In a recent study with 45 patients, we compared fl uorothy- Fig. 2 . A Overall survival of metabolic responders and metabolic nonresponders with locally advanced gastric cancer, calculated from the beginning of chemotherapy (CTx). Metabolic responders had signifi cantly improved survival compared to metabolic nonresponders (P = 0.002). B Overall survival in patients with locally advanced gastric cancer after complete resection, calculated from the day of the operation. Metabolic responders had signifi cantly improved survival compared to metabolic nonresponders (P = 0.02) and disease-free survival (P = 0.01) [28] . Therefore, before these fi ndings can be used routinely in the clinical setting these cutoffs have to be harmonized, and methodology has to be standardized and tested prospectively in a multicenter setting. Another open (Fig. 4) . In the future, the addition of FLT-PET to FDG-PET could improve the early evaluation of response to neoadjuvant treatment of gastric cancer.
Neoadjuvant treatment and surgical consequences in gastric cancer

Risk analysis
Severe chemotherapy-related complications inhibiting resection after chemotherapy are relatively rare. In the MAGIC study, 4 of 237 patients in the perioperative chemotherapy group died within 60 days after commencing treatment: 2 because of tumor progression and 2 because of cardiac events. In the French study, 4 of 113 patients with perioperative chemotherapy did not have a resection: 1 patient died of toxicity-related causes and 3 did not have a resection because of tumor progression [10, 11] .
Postoperative mortality was the same in both treatment arms in both randomized phase III studies. In the MAGIC trial, in the surgery-alone arm, 5.6% of patients died and 5.9% died in the perioperative chemotherapyarm; in the French trial, the corresponding numbers were 4% and 5%, respectively. The reported complication rate was higher in the MAGIC trial (45.3% for surgery alone, 45.7% for perioperative chemotherapy) than in the French trial (19% for surgery alone and 26% for perioperative chemotherapy). This may have been be due to the inclusion of minor complications in the analysis. Median hospital stay in both groups in the MAGIC trial was 13 days [10, 11] .
A matched-pair analysis, performed at the Technical University of Munich in 248 patients with neoadjuvant treatment compared to 248 with surgery alone, confi rmed these results. The overall complication rate was 29.1% after neoadjuvant chemotherapy and 28.9% after surgery alone; the in-hospital mortality was 3.2% and 5.5%; and the 30-day mortality was 2.0% and 2.8%, respectively. The median hospital stay was 14 days in both groups. No difference regarding type or incidence of complications could be found between the two groups (Table 5) .
Histopathology and prognosis
Signifi cantly more complete resections were achieved in the French randomized trial (87% versus 74%; P = 0.04) and in the Technical University of Munich matchedpair analysis (74% versus 58%; P = 0.0001). No exact histopathological workup of the resected specimens was performed in the MAGIC trial. But a curative resection according to the surgeon was achieved in 69% of the patients with perioperative chemotherapy and in 66% of the patients with primary resection; the complete resection rate of patients treated with radical surgery was in favor of perioperative chemotherapy (79% versus 70%; P = 0.018; Table 1 ). In both the MAGIC and the French trials, there was a trend to lower pN categories following preoperative chemotherapy. In the MAGIC trial, 84% of the patients in the chemotherapy arm were pN0 or 1 compared to 71% in the surgery-alone arm (P = 0.01); in the French trial, 33% of the patients in the chemotherapy arm and 20% in the surgery-alone arm were classifi ed as pN0 (P = 0.054) [10, 11] .
A downsizing of the primary tumor (pT0, 1 or 2) occurred in 52% of the patients in the MAGIC trial (P = 0.002) and in 42% of the patients in the French trial (P = 0.16) [10, 11] .
Both studies consistently showed signifi cantly improved progression-free and overall survivals for the patients with perioperative chemotherapy and surgery.
In conclusion, the effectiveness and superiority of perioperative chemotherapy followed by surgery compared to surgery alone was proven by both the randomized phase III studies described here (the MAGIC and French trials). There was no difference in morbidity, mortality, hospital stay, and incidence or type of complications between the two treatment groups in either trial. Histopathological results were improved by perioperative chemotherapy.
The new credo
Recently published randomized phase III studies have shown that induction chemotherapy is effective in locally advanced gastric cancer [10, 11] . Perioperative chemotherapy did not increase morbidity or mortality, but signifi cantly improved the patients' survival [10, 11] . It is generally accepted that responders have a signifi cantly improved survival compared to that in nonresponding patients [12] . Unfortunately, no standardized scores for clinical or histopathological response evaluation have been established so far, which makes studies hard to compare [5, 22, 27, 28] . There is a need for the homogenization of clinical and histopathological response scores after induction chemotherapy. Thus far, no prospectively tested clinical, histopathological, or molecular markers predicting response and/or prognosis are available for gastric cancer before induction therapy is started. Only the metabolic response has predicted histological response and survival with suffi cient accuracy [20, 28] . However, the relevant group of FDG-PET-nonavid patients makes the issue more complicated in gastric cancer than in AEG I and II [33, 34, 37, 38] . Response and survival for FDG-PET-nonavid patients was not signifi cantly better than that in metabolic nonresponders. Thus, alternative treatment concepts, such as immediate resection after 2 weeks of chemotherapy or adjustment of chemotherapy with or without adjuvant treatment for metabolic nonresponders, or modifi ed or potentially more intensive perioperative chemotherapy regimens -possibly including biologically targeted drugs or intensity-modulated high-precision radiotherapy -in initially FDG-PET-nonavid tumors could be considered (Fig. 5) . Generally, response-based strategies such as those in the MUNICON trial are feasible and recommendable in AEG I and II in clinical studies [29, 30] . The results of the MUNICON trial have now to be confi rmed in a prospective randomized multicenter trial. Because FDG-PET is less effective in gastric cancer than in AEG I and II for early response evaluation, other stratifi cation criteria such as FLT-PET or histopathological or molecular markers may gain importance in gastric cancer. In summary, the design of individualized response-based treatment concepts to improve patient survival is the challenge of the future. 
